About efmorocto cog alfa recombina
Recombinant factor VIII clotting factor
Used for
- Prevention and treatment of bleeding in haemophilia A
- Control of bleeding during and after surgery
Usual adult dose
Individualised by body weight, bleeding severity, factor levels, and treatment purpose; given intravenously.
Usual dose in children
Individualised by body weight, bleeding severity, factor levels, and treatment purpose; given intravenously.
Common side effects
- Headache
- Joint pain
- Rash
- Development of factor VIII inhibitors
Important warnings
- Factor VIII inhibitors may reduce treatment effectiveness.
- Severe allergic reactions can occur.
- Seek urgent care for symptoms of anaphylaxis.
- Dose and monitoring require specialist haemophilia care.
Pregnancy
Limited human data; use only when clinically needed, with specialist guidance.
Breastfeeding
It is unknown whether efmoroctocog alfa passes into breast milk; discuss use with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.